Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Secobarbital. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Secobarbital. |
| Buprenorphine | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Hydrocodone | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Magnesium sulfate | The therapeutic efficacy of Secobarbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Secobarbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Mirtazapine | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Orphenadrine | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Pramipexole | Secobarbital may increase the sedative activities of Pramipexole. |
| Rotigotine | Secobarbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Secobarbital. |
| Suvorexant | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Thalidomide | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Secobarbital. |
| Mefloquine | The therapeutic efficacy of Secobarbital can be decreased when used in combination with Mefloquine. |
| Orlistat | Orlistat can cause a decrease in the absorption of Secobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetaminophen | The metabolism of Acetaminophen can be increased when combined with Secobarbital. |
| Chloramphenicol | The metabolism of Secobarbital can be decreased when combined with Chloramphenicol. |
| Doxycycline | The serum concentration of Doxycycline can be decreased when it is combined with Secobarbital. |
| Felbamate | The serum concentration of Secobarbital can be increased when it is combined with Felbamate. |
| Griseofulvin | The serum concentration of Griseofulvin can be decreased when it is combined with Secobarbital. |
| Lamotrigine | The serum concentration of Lamotrigine can be decreased when it is combined with Secobarbital. |
| Mianserin | The therapeutic efficacy of Secobarbital can be decreased when used in combination with Mianserin. |
| Primidone | The risk or severity of adverse effects can be increased when Primidone is combined with Secobarbital. |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Secobarbital. |
| Pyridoxine | The metabolism of Secobarbital can be increased when combined with Pyridoxine. |
| Teniposide | The serum concentration of Teniposide can be decreased when it is combined with Secobarbital. |
| Ulipristal | The serum concentration of Ulipristal can be decreased when it is combined with Secobarbital. |
| Voriconazole | The serum concentration of Voriconazole can be decreased when it is combined with Secobarbital. |
| Topotecan | Secobarbital may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Secobarbital. |
| Sodium oxybate | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Secobarbital. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Secobarbital. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Secobarbital. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Secobarbital. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Secobarbital. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Secobarbital. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Secobarbital. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Secobarbital. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Secobarbital. |
| Aminophylline | The therapeutic efficacy of Secobarbital can be decreased when used in combination with Aminophylline. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum toxin type B. |
| Meperidine | Secobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine. |
| Somatostatin | The risk or severity of adverse effects can be increased when Somatostatin is combined with Secobarbital. |
| Ethanol | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Secobarbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Secobarbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Secobarbital is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Secobarbital is combined with Bezitramide. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Hydromorphone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Secobarbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Secobarbital is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Secobarbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine. |